CEOs from Bristol Myers Squibb, Johnson & Johnson and Merck faced tough questions from senators on why prices for drugs in the U.S. exceed those in other countries.

Novo Nordisk has reached confidential settlements with two Florida sellers of compounded versions of the mega-blockbuster semaglutide treatments Ozempic and Wegovy, the company said on Friday.

Takeda’s narcolepsy work has finally yielded a phase 2b win, albeit with a blemish. After axing one asset over liver toxicity, the Japanese drugmaker’s continued faith in the mechanism has been rewarded with a primary endpoint hit—but the midphase program only supports progression in one form of the disease.

Despite some turbulence at Catalent, including an 11% sales drop for the quarter, investors still seem to be buzzed about the stock after this week’s announcement that Novo Holdings is buying out the CDMO for $16.5 billion.

A mounting wave of recent research argues that high-volume hemodiafiltration may significantly improve outcomes for people with kidney failure compared to standard hemodialysis treatments.

After a string of IPO success stories for clinical-stage biotechs so far this year, two companies look set to test whether they can expect the same warm reaction on the public markets this morning despite not yet having a candidate in human trials.

The oncology drug supply crisis has entered its second year, and doctors still face "impossible choices" without access to standard-of-care therapies, ASCO's chief medical officer, Dr. Julie Gralow, testified this week. At a congressional hearing, Gralow proposed recommendations that could help ease the situation.